Relay Therapeutics (RLAY) Return on Capital Employed (2020 - 2026)
Relay Therapeutics' (RLAY) quarterly Return on Capital Employed came in at 47.0% in Q1 2026, down 103.0% year-on-year from 1566.77% in Q1 2025, and up 3.73% on a QoQ basis from 48.82% in Q4 2025.
Relay Therapeutics (RLAY) Return on Capital Employed (2020 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has 7 years of Return on Capital Employed data on file, last reported at 47.0% in Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 103.0% year-over-year to 47.0% in Q1 2026; TTM through Mar 2026 was 47.0%, a 103.0% decrease from a year earlier, with the FY2025 full-year figure at 42.0%, up 416.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 47.0%, up from 48.82% in the prior quarter.
- Over the last five years, Return on Capital Employed for RLAY reached as high as 27.96% in Q4 2022 and fell as low as 49.05% in Q3 2025.
- Historically, Return on Capital Employed has averaged 41.67% across 5 years, with a median of 44.13% in 2023.
- On a YoY basis, Return on Capital Employed climbed as much as 4799 bps in 2022 and fell as far as 97125 bps in 2022.
- Year by year, Return on Capital Employed stood at 27.96% in 2022, then tumbled by 58 bps to 44.13% in 2023, then increased by 1 bps to 43.82% in 2024, then retreated by 11 bps to 48.82% in 2025, then rose by 4 bps to 47.0% in 2026.
- Per Business Quant data, the three most recent Return on Capital Employed figures were 47.0% in Q1 2026, 48.82% in Q4 2025, and 49.05% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Relay Therapeutics | 3.31 Bn | 3.31 Bn | - | -47.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.00% |
| Dec 31, 2025 | -48.82% |
| Sep 30, 2025 | -49.05% |
| Jun 30, 2025 | -46.89% |
| Mar 31, 2025 | -45.97% |
| Dec 31, 2024 | -43.82% |
| Sep 30, 2024 | -47.20% |
| Jun 30, 2024 | -46.84% |
| Mar 31, 2024 | -44.96% |
| Dec 31, 2023 | -44.13% |
| Sep 30, 2023 | -40.02% |
| Jun 30, 2023 | -39.43% |
| Mar 31, 2023 | -33.83% |
| Dec 31, 2022 | -27.96% |
| Sep 30, 2022 | -30.72% |
| Jun 30, 2022 | -30.74% |
| Mar 31, 2022 | -41.07% |
| Dec 31, 2021 | -75.94% |
| Sep 30, 2021 | 940.54% |
| Jun 30, 2021 | -65.89% |